Physician profile
Grisel Mac Williams
NPI 1053396549
$4,723.76
in general payments reported to CMS, 2019-2025
28 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $966 · 2021: $1,027 · 2022: $691 · 2023: $565 · 2024: $481 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,144.22 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $489.73 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $481.65 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $452.51 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Esperion Therapeutics, INC. | $381.95 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.35 | 2019-2023 | Jardiance, Tradjenta |
| Pfizer INC. | $191.46 | 2019-2023 | |
| Abbvie INC. | $162.98 | 2021-2023 | |
| Amgen INC. | $144.02 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $132.52 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $104.36 | 2021-2025 | Zoryve |
| Exact Sciences Corporation | $100.25 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $94.74 | 2021-2022 | |
| Allergan, INC. | $78.15 | 2020 | |
| Merck Sharp & Dohme LLC | $74.98 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $58.24 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $45.11 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $42.66 | 2024 | Inspire |
| Mylan Specialty L.P. | $35.00 | 2022 | |
| Ascend Therapeutics US, LLC | $29.20 | 2021 | |
| Radius Health, INC. | $28.33 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.46 | 2023 | Jynarque |
| Biogen, INC. | $22.68 | 2021 | |
| Astellas Pharma US INC | $20.83 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.35 | 2021 | |
| Phadia US INC. | $19.07 | 2023 | Immunocap |
| Dexcom, INC. | $15.90 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $15.06 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grisel Mac Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.